HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer. Cherifi F, Da Silva A, Johnson A, Blanc-Fournier C, et al. BMC Cancer 2022;22:1081.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Cherifi F, Da Silva A, Johnson A, Blanc-Fournier C, et al. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer. BMC Cancer 2022;22:1081.
PMID: 36266623